Semaglutide vs Tirzepatide

Head-to-head evidence comparison — which supplement is right for you?

Quick answerNo interaction data — ask a pharmacist

Semaglutide vs Tirzepatide: Semaglutide has the stronger overall evidence (8.5 vs 7.8/10); they're alternatives for manage weight — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.

Semaglutide Edges Ahead

Semaglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.

Semaglutide2 wins

Tirzepatide0 wins

Which is right for you? Take the 60-second quiz Open in the full comparison tool

Sgl8.5

Semaglutide

Too few graded studiesLimited safety

Tir7.8

Tirzepatide

Too few graded studiesLimited safety

Evidence

Evidence Score

Best8.5/10

Studies: 455

Meta-analyses: 134

Level: Very Strong

Evidence Score

7.8/10

Studies: 133

Meta-analyses: 42

Level: Strong

Research findings

Verdict

Too few graded studies

Top outcomes

Blood sugar & glycemic controlToo few graded studies197
Weight managementToo few graded studies182
Cardiovascular outcomesToo few graded studies58

Verdict

Too few graded studies

Top outcomes

Weight managementToo few graded studies80
Glycemic & metabolic controlToo few graded studies53
Heart & blood pressureToo few graded studies20

Shared outcomes (3)

Outcomes where both Semaglutide and Tirzepatide have evidence — compare verdict strength side-by-side.

Weight managementToo few graded studies182Too few graded studies80
Glycemic & metabolic controlToo few graded studies197Too few graded studies53
Heart & blood pressureToo few graded studies58Too few graded studies20

Dosage & timing

Recommended Dosage:

Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.
US FDA labeling includes a boxed warning about thyroid C-cell tumors: semaglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.
Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.
Risk of gallbladder disease (gallstones, cholecystitis), particularly with rapid weight loss.
Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are very common, especially during dose escalation.
Post-marketing reports of ileus (severely slowed gut motility).
May worsen pre-existing diabetic retinopathy, attributed to rapid improvement in glucose control — ensure ophthalmologic monitoring in patients with a history of diabetic retinopathy.
Weight loss includes loss of lean muscle mass — pair with resistance training and adequate protein.
FDA has warned about COMPOUNDED / grey-market semaglutide: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.
Not for cosmetic weight loss without a genuine medical indication.
May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Subcutaneous once-weekly injection (Ozempic / Wegovy)

Recommended Dosage:

Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)

Warnings

PRESCRIPTION DRUG — this is an FDA-approved medication (Mounjaro / Zepbound), not a dietary supplement. Use only under medical supervision for an approved indication.
US FDA labeling includes a boxed warning about thyroid C-cell tumors: tirzepatide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.
Pancreatitis has been reported — discontinue and seek care for severe, persistent abdominal pain; avoid in those with a pancreatitis history.
Gallbladder disease (gallstones, cholecystitis) can occur, partly related to rapid weight loss.
Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are common, especially during dose escalation.
A portion of the weight lost is lean (muscle) mass — prioritize adequate protein and resistance exercise.
FDA has warned about compounded and grey-market tirzepatide of unverified identity, purity, and dose — do not source outside a legitimate prescription.
Not for cosmetic or off-label use without a medical indication and supervision.
May reduce the efficacy of oral contraceptives via delayed gastric emptying — use a backup method when starting and after dose increases.
Benefits depend on continued use — randomized withdrawal data show substantial weight regain after stopping.

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Once-weekly subcutaneous injection (Mounjaro / Zepbound)

Safety

Limited safetyTie

Drug Interactions:

Other GLP-1 receptor agonists (severe)
Insulin and sulfonylureas (moderate)
Oral medications (general) (moderate)

Side Effects:

NauseaVomiting / diarrhea / constipationGallbladder disease (cholelithiasis / cholecystitis)

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2) (a contraindication under the US label)

Limited safetyTie

Drug Interactions:

Oral contraceptives (moderate)
Insulin and sulfonylureas (moderate)
Oral medications generally (moderate)

Side Effects:

NauseaDiarrheaVomiting

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label)
Multiple endocrine neoplasia syndrome type 2 (MEN2) (a contraindication under the US label)

Shared goals

Manage weightTirzepatide

Semaglutide88/100

Tirzepatide90/100

Manage blood sugarTie

Semaglutide85/100

Tirzepatide85/100

Metabolic healthTirzepatide

Semaglutide70/100

Tirzepatide72/100

What you'll notice

🩸 Improved glycemic controlpositive

Weeks to months

⚖️ Substantial weight losspositive

Months (titrated over 16-20 weeks)

❤️ Reduced cardiovascular eventspositive

Months to years

🤢 GI adverse effects (very common)trade-off

Especially during dose escalation

🩸 Strong glycemic controlpositive

Weeks to months

⚖️ Large weight losspositive

Months (dose-escalated over ~20 weeks)

😴 Reduced sleep-apnea severitypositive

Weeks to months

🤢 GI side effects (common)negative

Mostly during titration

Key studies

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).

N Engl J Med (2021) · Rct · n=1961

Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).

N Engl J Med (2023) · Rct · n=17604

Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).

N Engl J Med (2016) · Rct · n=3297

Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks

All Semaglutide studies

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

N Engl J Med (2021) · Rct · n=1879

Open-label 40-week phase-3 head-to-head RCT (SURPASS-2) in 1879 patients with type 2 diabetes, tirzepatide 5/10/15 mg vs semaglutide 1 mg

Tirzepatide Once Weekly for the Treatment of Obesity.

N Engl J Med (2022) · Rct · n=2539

72-week phase-3 double-blind RCT (SURMOUNT-1) in 2539 adults with obesity (without diabetes), tirzepatide 5/10/15 mg vs placebo

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.

N Engl J Med (2025) · Rct · n=751

Phase-3b open-label head-to-head RCT (SURMOUNT-5) in 751 adults with obesity but without diabetes, max-tolerated tirzepatide vs max-tolerated semaglutide

All Tirzepatide studies

Frequently asked questions

Is Semaglutide better than Tirzepatide?

Semaglutide has a higher evidence score (8.5/10 vs 7.8/10) and wins in 2 of 3 categories.

Is Semaglutide or Tirzepatide better for manage weight?

For manage weight, Tirzepatide has a higher relevance score (90 vs 88).

Can I take Semaglutide and Tirzepatide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Related comparisons

Liraglutide vs Semaglutide AREDS2 Formula vs Semaglutide Dulaglutide vs Semaglutide Liraglutide vs Tirzepatide Thiamine vs Tirzepatide AREDS2 Formula vs Tirzepatide

Still deciding between Semaglutide and Tirzepatide?

The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.

Get your personalised pick Semaglutide details Tirzepatide details

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.

US FDA labeling includes a boxed warning about thyroid C-cell tumors: semaglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.

Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.

Risk of gallbladder disease (gallstones, cholecystitis), particularly with rapid weight loss.

Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are very common, especially during dose escalation.

Post-marketing reports of ileus (severely slowed gut motility).

May worsen pre-existing diabetic retinopathy, attributed to rapid improvement in glucose control — ensure ophthalmologic monitoring in patients with a history of diabetic retinopathy.

Weight loss includes loss of lean muscle mass — pair with resistance training and adequate protein.

FDA has warned about COMPOUNDED / grey-market semaglutide: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.

Not for cosmetic weight loss without a genuine medical indication.

May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Warnings

PRESCRIPTION DRUG — this is an FDA-approved medication (Mounjaro / Zepbound), not a dietary supplement. Use only under medical supervision for an approved indication.

US FDA labeling includes a boxed warning about thyroid C-cell tumors: tirzepatide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.

Pancreatitis has been reported — discontinue and seek care for severe, persistent abdominal pain; avoid in those with a pancreatitis history.

Gallbladder disease (gallstones, cholecystitis) can occur, partly related to rapid weight loss.

Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are common, especially during dose escalation.

A portion of the weight lost is lean (muscle) mass — prioritize adequate protein and resistance exercise.

FDA has warned about compounded and grey-market tirzepatide of unverified identity, purity, and dose — do not source outside a legitimate prescription.

Not for cosmetic or off-label use without a medical indication and supervision.

May reduce the efficacy of oral contraceptives via delayed gastric emptying — use a backup method when starting and after dose increases.

Benefits depend on continued use — randomized withdrawal data show substantial weight regain after stopping.

Frequently asked questions

Is Semaglutide better than Tirzepatide?

Semaglutide has a higher evidence score (8.5/10 vs 7.8/10) and wins in 2 of 3 categories.

Is Semaglutide or Tirzepatide better for manage weight?

For manage weight, Tirzepatide has a higher relevance score (90 vs 88).

Can I take Semaglutide and Tirzepatide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.